Data from Boehringer Ingelheim’s LUX-Lung 6 trial, presented at the official American Society of Clinical Oncology (ASCO) Annual Conference, demonstrate that patients treated with the novel, investigational compound afatinib* lived for almost one year before their tumour started to grow again, compared to less than half a year for those on standard chemotherapy (gemcitabine/cisplatin). Tumour assessment was based on independent review of the data showing progression-free survival (PFS) of 11.0 months for afatinib* and"...

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide Celgene in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while"...

2013 ASCO Annual Meeting

Takeda Pharmaceutical Company Limited (TSE:4502) today announced interim data from a Phase 1/2, open-label, multicenter study with ADCETRIS® (brentuximab vedotin) in pediatric patients diagnosed with CD30-positive relapsed or refractory Hodgkin lymphoma (HL) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Data were presented from the Phase 1 portion of the study, which evaluated the safety, maximum"...

In advance of the American Society of Clinical Oncology (ASCO) Annual Meeting, Quintiles today announced the release of its perspective on two areas of focus for clinical oncologists – the impact of patient selection in early-phase studies and the use of biomarkers in the treatment of hematologic malignancies.

The first of these reports, Tomorrow’s"...

Cellogique Corporation and Croma Princess are happy to announce the expansion of distribution of Croma Princess fillers and mesotherapy to include Saudi Arabia and the United Arab Emirates.

Croma Princess suggests an alternative to plastic surgery with their innovative and sophisticated fillers and mesotherapy. Croma Princess’ revolutionary hyaluronic dermal filler"...

Cellogique Corporation and Colorescience are pleased to announce their new partnership for the distribution of a revolutionary line of mineral makeup in the Middle East and Turkey.

Colorescience boasts “makeup that does more,” by combining the art of makeup with the science of skincare. This cutting edge line of makeup is comprised of high quality ingredients"...

If you are on the fence about getting LASIK in Dubai then here are few reasons as to why you should go right ahead and get it done in order to free yourself from glasses or contact lenses in a matter of minutes!

LASIK in Dubai is immensely popular as it ensures immediate results unlike any other procedures. Even though your eyes will continue healing for a short period of"...

• Over two thirds of physicians point out preventing ischaemic stroke as the most important treatment goal for patients with atrial fibrillation (AF)1
• Physicians highlight the vital need for awareness of the true incidence of ischaemic stroke1
• 92% of all strokes in patients with AF are ischaemic strokes2, making ischaemic stroke prevention a key treatment priority

Not intended for media in the UK, the US or Canada

New"...

European Medicines Agency Accepts Regulatory Submission of Type II Variation for ABRAXANE for the Treatment of Advanced Pancreatic Cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation (Celgene) (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application"...

For Non-U.S. and Non-UK media

Boehringer Ingelheim and Eli Lilly & Company have today launched an educational digital game for type 2 diabetes called Complications Combat. The game, available for desktop and iPad users, is designed to raise awareness of the many complications associated with type 2 diabetes and the challenges physicians and patients face when considering"...